Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

6.82
-0.6800-9.07%
Volume:17.36K
Turnover:115.24K
Market Cap:5.66M
PE:-0.49
High:7.13
Open:6.28
Low:6.25
Close:7.50
52wk High:60.00
52wk Low:6.25
Shares:829.40K
Float Shares:752.35K
Volume Ratio:0.09
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.8684
EPS(LYR):-15.0475
ROE:-240.25%
ROA:-119.22%
PB:3.72
PE(LYR):-0.45

Loading ...

Nexalin Technology Inc trading halted, volatility trading pause

TIPRANKS
·
Yesterday

NASDAQ Trade Halt Continues Volatility Trading Pause at 09:43 Am

Reuters
·
Yesterday

Nexalin Technology Inc trading halted, news pending

TIPRANKS
·
Aug 29

Nexalin Technology Announces Reverse Stock Split

THOMSON REUTERS
·
Aug 27

Nexalin Technology - Approves 1-for-30 Reverse Stock Split

THOMSON REUTERS
·
Aug 27

Morgan Stanley Keeps Their Buy Rating on Nuix Ltd. (NXL)

TIPRANKS
·
Aug 26

Jefferies Remains a Buy on Nuix Ltd. (NXL)

TIPRANKS
·
Aug 26

Nuix (ASX:NXL) Shares Ask Whether Neo Growth Justifies Premium P/E

Simply Wall St.
·
Aug 25

Nexalin Technology Enters USD 1.17 Million Unsecured Note Financing with Institutional Investor

Reuters
·
Aug 22

Nexalin Technology Prices Registered Direct Offering of 2,419,355 Shares at $0.31 Each

Reuters
·
Aug 21

Nexalin Falls Below NASDAQ Stockholders’ Equity Minimum, Faces Delisting Risk

Reuters
·
Aug 17

Nexalin Q2 FY26 Net Loss Widens 42% to $2.24 Million; Revenue Drops 83% to $12,161

Reuters
·
Aug 13

Nexalin Technology Menggelar Rapat Tahunan Pemegang Saham; Kuorum Tercapai 63,2%

Reuters
·
Aug 12

Nexalin Technology Inc Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Jul 31

RBC Capital Keeps Their Buy Rating on Nuix Ltd. (NXL)

TIPRANKS
·
Jul 29

Nexalin Appeals NASDAQ Delisting Notice After Failing $1 Minimum Bid Requirement

Reuters
·
Jul 28

Nexalin Technology Announces Annual Shareholder Meeting

Reuters
·
Jun 30

Nexalin Technology investigator wins award for neurostimulation research

TIPRANKS
·
Jun 23

Nexalin Technology lowers shareholder meeting quorum requirement to one-third in bylaw overhaul

Reuters
·
Jun 18

Nexalin says open-label pilot trial data show 77.8% anxiety response with DIFS brain-stimulation device

Reuters
·
Jun 16